IL187085A0 - Combination therapy comprising diaryl ureas for treating diseases - Google Patents
Combination therapy comprising diaryl ureas for treating diseasesInfo
- Publication number
- IL187085A0 IL187085A0 IL187085A IL18708507A IL187085A0 IL 187085 A0 IL187085 A0 IL 187085A0 IL 187085 A IL187085 A IL 187085A IL 18708507 A IL18708507 A IL 18708507A IL 187085 A0 IL187085 A0 IL 187085A0
- Authority
- IL
- Israel
- Prior art keywords
- combination therapy
- treating diseases
- diaryl ureas
- diaryl
- ureas
- Prior art date
Links
- 235000013877 carbamide Nutrition 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- -1 diaryl ureas Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011478 | 2005-05-27 | ||
| EP05011475 | 2005-05-27 | ||
| EP05011476 | 2005-05-27 | ||
| PCT/EP2006/004523 WO2006125539A2 (en) | 2005-05-27 | 2006-05-13 | Combination therapy comprising diaryl ureas for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL187085A0 true IL187085A0 (en) | 2008-08-07 |
Family
ID=37052960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL187085A IL187085A0 (en) | 2005-05-27 | 2007-11-01 | Combination therapy comprising diaryl ureas for treating diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090306020A1 (https=) |
| EP (1) | EP1888065A2 (https=) |
| JP (1) | JP2008545670A (https=) |
| KR (1) | KR20080012902A (https=) |
| AU (1) | AU2006251428A1 (https=) |
| BR (1) | BRPI0610090A2 (https=) |
| CA (1) | CA2609387A1 (https=) |
| IL (1) | IL187085A0 (https=) |
| MX (1) | MX2007014920A (https=) |
| WO (1) | WO2006125539A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| SG160364A1 (en) * | 2005-03-07 | 2010-04-29 | Bayer Schering Pharma Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| TW200835507A (en) * | 2006-12-05 | 2008-09-01 | Vioquest Pharmaceuticals Inc | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| JP5885012B2 (ja) | 2007-01-19 | 2016-03-15 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ | Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置 |
| US7947723B2 (en) | 2008-02-01 | 2011-05-24 | Spelman College | Synthesis and anti-proliferative effect of benzimidazole derivatives |
| US8586802B2 (en) * | 2008-04-09 | 2013-11-19 | Dow Global Technologies Llc | Multi-stage process and apparatus for recovering dichlorohydrins |
| TW201012467A (en) | 2008-09-16 | 2010-04-01 | Taiho Pharmaceutical Co Ltd | Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid |
| CA2754343A1 (en) * | 2009-04-09 | 2010-10-14 | Oncothyreon, Inc. | Methods and compositions of pi-3 kinase inhibitors for treating fibrosis |
| NZ620174A (en) | 2009-09-16 | 2016-08-26 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
| EP2519664A4 (en) | 2009-12-30 | 2014-03-12 | Avila Therapeutics Inc | LIGAND-RELATED COVALENTS MODIFYING A PROTEIN |
| ES2385276B1 (es) * | 2010-02-25 | 2013-07-05 | Universidad Del País Vasco | Compuestos para el tratamiento de alzheimer. |
| CA2805874A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| CA3240745A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of erk and raf inhibitors |
| CN114751899B (zh) * | 2022-04-24 | 2024-03-29 | 贵州医科大学 | 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378725A (en) * | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| MXPA04007832A (es) * | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| EP1494675A4 (en) * | 2002-04-08 | 2006-07-19 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| EA010485B1 (ru) * | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| BRPI0508970A (pt) * | 2004-03-19 | 2007-08-21 | Penn State Res Found | método combinatórios e composições para o tratamento de melanoma |
| AU2005281704A1 (en) * | 2004-09-06 | 2006-03-16 | Nycomed Gmbh | Novel pyrazolopyrimidines |
-
2006
- 2006-05-13 CA CA002609387A patent/CA2609387A1/en not_active Abandoned
- 2006-05-13 MX MX2007014920A patent/MX2007014920A/es not_active Application Discontinuation
- 2006-05-13 WO PCT/EP2006/004523 patent/WO2006125539A2/en not_active Ceased
- 2006-05-13 KR KR1020077027599A patent/KR20080012902A/ko not_active Withdrawn
- 2006-05-13 US US11/920,952 patent/US20090306020A1/en not_active Abandoned
- 2006-05-13 EP EP06761913A patent/EP1888065A2/en not_active Withdrawn
- 2006-05-13 BR BRPI0610090-2A patent/BRPI0610090A2/pt not_active Application Discontinuation
- 2006-05-13 JP JP2008512729A patent/JP2008545670A/ja active Pending
- 2006-05-13 AU AU2006251428A patent/AU2006251428A1/en not_active Abandoned
-
2007
- 2007-11-01 IL IL187085A patent/IL187085A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008545670A (ja) | 2008-12-18 |
| AU2006251428A1 (en) | 2006-11-30 |
| EP1888065A2 (en) | 2008-02-20 |
| CA2609387A1 (en) | 2006-11-30 |
| KR20080012902A (ko) | 2008-02-12 |
| MX2007014920A (es) | 2008-04-09 |
| BRPI0610090A2 (pt) | 2008-12-09 |
| US20090306020A1 (en) | 2009-12-10 |
| WO2006125539A2 (en) | 2006-11-30 |
| WO2006125539A3 (en) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL187085A0 (en) | Combination therapy comprising diaryl ureas for treating diseases | |
| IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
| ZA200805877B (en) | Pyridiazinone derivatives for tumour treatment | |
| IL188430A0 (en) | Treatment of tumors | |
| ZA200709620B (en) | Methods for treating drug resistant cancer | |
| SI2422786T1 (sl) | Nove farmacevtske kombinacije za zdravljenje respiratornih obolenj | |
| IL185444A0 (en) | Novel drugs for treating respiratory diseases | |
| IL183520A0 (en) | Preventive or therapeutic agent for sleep disorder | |
| EP1830847A4 (en) | ANTICANCER TREATMENT | |
| IL178920A0 (en) | Treatment for pancreatic cancer | |
| ZA200810199B (en) | Rinse-off therapeutic agents for treating skin | |
| GB0428187D0 (en) | Cancer treatment | |
| GB0413346D0 (en) | Treating cancer | |
| EP1867640A4 (en) | MEANS FOR TREATING SOLID TUMORS | |
| IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| IL226362A0 (en) | compounds, and methods for treating cancer | |
| GB0517387D0 (en) | Combinations for the treatment of cancer | |
| ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
| EP1890711A4 (en) | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES | |
| GB0425854D0 (en) | Therapeutic treatment | |
| GB0525535D0 (en) | Tumour treatment | |
| EP1719514A4 (en) | MEDICAMENT FOR TREATING PAIN | |
| GB0408752D0 (en) | Therapeutic treatment | |
| GB0404675D0 (en) | Cancer treatment | |
| GB0507685D0 (en) | Cancer treatment |